- Home
- LLYVK vs STVN Comparison
LLYVK vs STVN Comparison
Compare LLYVK & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLYVK | STVN |
|---|---|---|
| Founded | 1991 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Broadcasting | Containers/Packaging |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LLYVK | STVN |
|---|---|---|
| Price | $85.08 | $20.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.38 |
| AVG Volume (30 Days) | ★ 359.0K | 329.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $1,373,219,524.00 |
| Revenue This Year | N/A | $8.42 |
| Revenue Next Year | $10.22 | $9.52 |
| P/E Ratio | ★ N/A | $34.98 |
| Revenue Growth | N/A | ★ 6.97 |
| 52 Week Low | $60.55 | $17.81 |
| 52 Week High | $102.62 | $28.00 |
Technical Indicators
Market Signals| Indicator | LLYVK | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 39.09 |
| Support Level | $80.19 | $20.62 |
| Resistance Level | $83.58 | $23.88 |
| Average True Range (ATR) | 2.49 | 1.14 |
| MACD | 1.03 | -0.08 |
| Stochastic Oscillator | 86.60 | 10.68 |
Price Performance
Historical ComparisonAbout LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.